Scholar Rock Holding Management

Management criteria checks 4/4

Scholar Rock Holding's CEO is Jay Backstrom, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is $4.11M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.028% of the company’s shares, worth $774.47K. The average tenure of the management team and the board of directors is 2.1 years and 7.7 years respectively.

Key information

Jay Backstrom

Chief executive officer

US$4.1m

Total compensation

CEO salary percentage	15.2%
CEO tenure	2.1yrs
CEO ownership	0.03%
Management average tenure	2.1yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

CEO Compensation Analysis

How has Jay Backstrom's remuneration changed compared to Scholar Rock Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$226m
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$183m
Dec 31 2023	US$4m	US$624k	-US$166m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$7m	US$159k	-US$135m

Compensation vs Market: Jay's total compensation ($USD4.11M) is below average for companies of similar size in the US market ($USD6.60M).

Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.

CEO

Jay Backstrom (69 yo)

2.1yrs

Tenure

US$4,111,853

Compensation

Dr. Jay Thomas Backstrom, M.D., M.P.H., serves as Non-Executive Director of LAVA Therapeutics N.V. since June 2022. He serves as Director at Be Biopharma, Inc. since December 2021. He had served as a Direc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jay Backstrom	President	2.1yrs	US$4.11m	0.028% $ 774.5k
Edward Myles	CFO, COO & Treasurer	4.3yrs	US$2.01m	0% $ 0
Tracey Sacco	Chief Commercial Officer	1.8yrs	US$2.28m	0% $ 0
Mo Qatanani	Chief Scientific Officer	less than a year	no data	0.022% $ 604.4k
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	no data	no data
Junlin Ho	General Counsel & Corporate Secretary	4.7yrs	US$2.13m	0.079% $ 2.2m
Caryn Parlavecchio	Chief Human Resources Officer	3.3yrs	no data	0.043% $ 1.2m
Lisa Price	Senior Vice President of Human Resources	no data	no data	no data
Erin Moore	Senior Vice President of Finance	no data	no data	no data
Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	4.7yrs	no data	no data
Jing Marantz	Chief Medical Officer	2yrs	no data	0.078% $ 2.2m
Beth Shafer	Chief Business Officer	less than a year	no data	no data

2.1yrs

Average Tenure

51.5yo

Average Age

Experienced Management: SRRK's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jay Backstrom	President	2.1yrs	US$4.11m	0.028% $ 774.5k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	11yrs	US$299.20k	0.040% $ 1.1m
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	no data
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	8.1yrs	US$305.70k	0.033% $ 936.1k
Leonard Zon	Member of Scientific Advisory Board	no data	no data	no data
Daniel Rifkin	Member of Scientific Advisory Board	no data	no data	no data
Kristina Burow	Independent Director	10.3yrs	US$300.34k	0.0057% $ 159.7k
Joan Massague	Member of Scientific Advisory Board	no data	no data	no data
David Hallal	Independent Chairman of the Board	7.3yrs	US$416.70k	0.31% $ 8.7m
Scott L. Friedman	Member of Scientific Advisory Board	no data	no data	no data
Barry Coller	Member of Scientific Advisory Board	no data	no data	no data
Joshua Reed	Independent Director	3.7yrs	US$305.70k	0% $ 0

7.7yrs

Average Tenure

69yo

Average Age

Experienced Board: SRRK's board of directors are considered experienced (7.7 years average tenure).

Scholar Rock Holding Management

Management criteria checks 4/4

Key information

Recent management updates

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

CFO, COO & Treasurer notifies of intention to sell stock

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)